Prospect: information for the patient
Fesoterodine Alter 4 mg prolonged-release EFG tablets
Fesoterodine Alter 8 mg prolonged-release EFG tablets
Fesoterodine, fumarate
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
This medication contains an active ingredient called fesoterodine fumarate and is a treatment for the so-called antimuscarinics, which reduce the activity of an overactive bladder and is used in adults to treat symptoms.
Fesoterodine treats the symptoms of an overactive bladder, such as:
Do not take Fesoterodina Alter
Warnings and precautions
Consult your doctor or pharmacist before starting to take Fesoterodina Alter.
Fesoterodina may not be suitable for you at all times.Talk to your doctorbefore taking fesoterodina in any of the following cases:
Cardiovascular problems:Inform your doctorif you have any of the following conditions:
Children and adolescents
Do not give this medication to children and adolescents under 18 years of age because its safety and efficacy have not been established in this age group.
Other medications and Fesoterodina Alter
Inform your doctor or pharmacist if you are taking or have taken recently or may need to take any other medication. Your doctor will tell you if you can use fesoterodina with other medications.
Please inform your doctor if you are taking medications from the list below. Taking these medications at the same time as fesoterodina may produce adverse effects such as dry mouth, constipation, difficulty emptying the urinary bladder, or more severe or frequent drowsiness.
Please indicate to your doctor if you are taking any of the following medications:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
You should not take fesoterodina if you are pregnant, as its effects on pregnancy and the newborn are unknown.
Fesoterodina is not known to be excreted in breast milk; therefore, do not breastfeed during treatment with this medication.
Driving and operating machinery
Fesoterodina may cause blurred vision, dizziness, and drowsiness. If you experience any of these effects, do not drive or operate tools or machinery.
Fesoterodina Alter contains fructose and lactose
If your doctor has indicated that you (or your child) have a condition that makes you intolerant to certain sugars, or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which the patient cannot break down fructose, consult your doctor before taking this medication.
This medication contains lactose. If your doctor has indicated that you are intolerant to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
The recommended initial dose is one 4 mg fesoterodina tablet per day. Depending on how you respond to the medication, your doctor may prescribe a higher dose; one 8 mg fesoterodina tablet per day.
You should swallow the tablet whole with a glass of water. Do not chew the tablet. This medication can be taken with or without food.
To help you remember to take your medication, it may be easier to take it at the same time every day.
If you take more Fesoterodina Alter than you should
If you have taken more tablets than you were told to take or if someone else has accidentally taken your tablets, contact your doctor or hospital immediately. Show them the packaging of the tablets.
If you forgot to take Fesoterodina Alter
If you have forgotten to take a tablet, take it as soon as you remember, but do not take more than one tablet in a day. Do not take a double dose to make up for missed doses.
If you interrupt treatment with Fesoterodina Alter
Do not stop treatment with fesoterodina without first talking to your doctor, as symptoms of overactive bladder may return or worsen when you stop taking this medication.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Some side effects can be serious
Other side effects
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and in the blister pack, after “CAD”. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Store in the original packaging to protect from moisture.
Composition of Fesoterodina Alter
Fesoterodina Alter 4 mg: Each prolonged-release tablet contains 4 mg of fumarate of fesoterodina, equivalent to 3.1 mg of fesoterodina.
Fesoterodina Alter 8 mg: Each prolonged-release tablet contains 8 mg of fumarate of fesoterodina, equivalent to 6.2 mg of fesoterodina.
Tablet core: fructose, lactose monohydrate-celulose microcrystalline spheres, hypromellose, dibehenate of glycerol, talc.
Tablet coating: poly(vinyl alcohol), titanium dioxide (E171), macrogol, talc, and carmine lake (E132).
Appearance of the product and contents of the packaging
Fesoterodina Alter 4 mg: Film-coated tablets, 13.1 x 6.0 mm, blue, eliptical, biconvex, with the engraving “F4” on one face.
Fesoterodina Alter 8 mg: Film-coated tablets, 13.1 x 6.0 mm, dark blue, eliptical, biconvex, with the engraving “F8” on one face.
Fesoterodina Alter is available in aluminum-aluminum blisters, in packs containing 28 tablets.
Marketing Authorization Holder
Laboratorios Alter, S.A.
C/ Mateo Inurria 30
28036 Madrid
Spain
Responsible for manufacturing
Laboratorios Normon, S.A.
Ronda de Valdecarrizo 6
28760 Tres Cantos, Madrid
Spain
Or
Laboratorios Liconsa, S.A.
Avda. Miralcampo 7
Polígono Industrial Miralcampo
19200 Azuqueca de Henares, Guadalajara
Spain
Last review date of this leaflet:
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.